Endo, Inc.
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It … Read more
Endo, Inc. (NDOI) - Total Assets
Latest total assets as of March 2025: $4.19 Billion USD
Based on the latest financial reports, Endo, Inc. (NDOI) holds total assets worth $4.19 Billion USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Endo, Inc. - Total Assets Trend (2023–2024)
This chart illustrates how Endo, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Endo, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Endo, Inc.'s total assets of $4.19 Billion consist of 33.9% current assets and 66.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.9% |
| Accounts Receivable | $415.92 Million | 9.6% |
| Inventory | $527.74 Million | 12.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.82 Billion | 41.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how Endo, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Endo, Inc.'s current assets represent 33.9% of total assets in 2024, an increase from 32.5% in 2023.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2024, down from 15.1% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, a decrease from 54.0% in 2023.
- Asset Diversification: The largest asset category is intangible assets at 41.7% of total assets.
Endo, Inc. Competitors by Total Assets
Key competitors of Endo, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Endo, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Endo, Inc. generates 0.39x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Endo, Inc. is currently not profitable relative to its asset base.
Endo, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 3.10 | 3.10 |
| Quick Ratio | 2.02 | 2.64 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $963.14 Million | $ 1.13 Billion | $ 1.13 Billion |
Endo, Inc. - Advanced Valuation Insights
This section examines the relationship between Endo, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | $4.35 Billion |
| Market Capitalization | $1.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Endo, Inc.'s assets below their book value (0.23 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Endo, Inc.'s assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Endo, Inc. (2023–2024)
The table below shows the annual total assets of Endo, Inc. from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.35 Billion | -15.27% |
| 2023-12-31 | $5.14 Billion | -- |